196 related articles for article (PubMed ID: 24417770)
1. Hypersensitivity to oxaliplatin: clinical features and risk factors.
Parel M; Ranchon F; Nosbaum A; You B; Vantard N; Schwiertz V; Gourc C; Gauthier N; Guedat MG; He S; Kiouris E; Alloux C; Vial T; Trillet-Lenoir V; Freyer G; Berard F; Rioufol C
BMC Pharmacol Toxicol; 2014 Jan; 15():1. PubMed ID: 24417770
[TBL] [Abstract][Full Text] [Related]
2. Hypersensitivity Reactions to Oxaliplatin: Identifying the Risk Factors and Judging the Efficacy of a Desensitization Protocol.
Okayama T; Ishikawa T; Sugatani K; Yoshida N; Kokura S; Matsuda K; Tsukamoto S; Ihara N; Kuriu Y; Nakanishi M; Nakamura T; Kamada K; Katada K; Uchiyama K; Takagi T; Handa O; Konishi H; Yagi N; Naito Y; Otsuji E; Hosoi H; Miki T; Itoh Y
Clin Ther; 2015 Jun; 37(6):1259-69. PubMed ID: 25862137
[TBL] [Abstract][Full Text] [Related]
3. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review.
Kim BH; Bradley T; Tai J; Budman DR
Oncology; 2009; 76(4):231-8. PubMed ID: 19246947
[TBL] [Abstract][Full Text] [Related]
4. Incidence and Risk of Oxaliplatin-Induced Hypersensitivity in Patients with Asymptomatic Prior Exposure: A Prospective Observational Study.
Sohn KH; Kang DY; Kim JY; Lee SY; Lee KH; Han SW; Kang HR
J Allergy Clin Immunol Pract; 2018; 6(5):1642-1648.e2. PubMed ID: 29454708
[TBL] [Abstract][Full Text] [Related]
5. Overcoming oxaliplatin hypersensitivity: different strategies are needed according to the severity and previous exposure.
Lee SY; Kang HR; Song WJ; Lee KH; Han SW; Cho SH
Cancer Chemother Pharmacol; 2014 May; 73(5):1021-9. PubMed ID: 24696124
[TBL] [Abstract][Full Text] [Related]
6. Clinical Analysis of Hypersensitivity Reactions to Oxaliplatin Among Colorectal Cancer Patients.
Shen Y; Li C; Liu W; Mao W; Qian H; Wang H; Xu Q
Oncol Res; 2018 Jun; 26(5):801-807. PubMed ID: 29295722
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of reintroducing oxaliplatin to patients with colorectal cancer after mild hypersensitivity reactions.
Park SJ; Lee KY; Park WS; Min SY
Oncology; 2013; 85(6):323-7. PubMed ID: 24247529
[TBL] [Abstract][Full Text] [Related]
8. Hypersensitivity reactions associated with oxaliplatin.
Saif MW
Expert Opin Drug Saf; 2006 Sep; 5(5):687-94. PubMed ID: 16907658
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization.
Wong JT; Ling M; Patil S; Banerji A; Long A
J Allergy Clin Immunol Pract; 2014; 2(1):40-5. PubMed ID: 24565767
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and risk factors of oxaliplatin-related hypersensitivity reactions.
Shao YY; Hu FC; Liang JT; Chiu WT; Cheng AL; Yang CH
J Formos Med Assoc; 2010 May; 109(5):362-8. PubMed ID: 20497869
[TBL] [Abstract][Full Text] [Related]
11. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol.
Syrigou EI; Karapanagiotou EM; Alamara CV; Boura PG; Saif MW; Syrigos KN
Clin Colorectal Cancer; 2009 Apr; 8(2):106-9. PubMed ID: 19739272
[TBL] [Abstract][Full Text] [Related]
12. Clinical Features of Oxaliplatin Induced Hypersensitivity Reactions and Therapeutic Approaches.
Bano N; Najam R; Qazi F; Mateen A
Asian Pac J Cancer Prev; 2016; 17(4):1637-41. PubMed ID: 27221832
[TBL] [Abstract][Full Text] [Related]
13. Simplified Graded Infusion Strategy for Mitigation of Oxaliplatin Hypersensitivity.
Alonso Martinez S; Segal NH; Cercek A; Yaeger R; Stadler Z; Kemeny NE; Nusrat M; Shahrokni A; Connell L; Saltz LB
Clin Colorectal Cancer; 2022 Jun; 21(2):149-153. PubMed ID: 35125319
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence of Branded and Generic Oxaliplatin: From Preclinical Assessment to Clinical Incidence of Hypersensitivity Reactions.
Tampellini M; Benedetto S; Rubatto E; Baratelli C; DI Scipio F; Pirro E; Brizzi MP; Sonetto C; DI Maio M; Berta GN; Scagliotti GV
Anticancer Res; 2016 Oct; 36(10):5163-5170. PubMed ID: 27798876
[TBL] [Abstract][Full Text] [Related]
15. Hypersensitivity reactions to oxaliplatin: experience in a single institute.
Siu SW; Chan RT; Au GK
Ann Oncol; 2006 Feb; 17(2):259-61. PubMed ID: 16282245
[TBL] [Abstract][Full Text] [Related]
16. Incidence of oxaliplatin hypersensitivity reaction among colorectal cancer patients: A 5-year retrospective study.
Palapinyo S; Klaewsongkram J; Sriuranpong V; Areepium N
Pharm Pract (Granada); 2022; 20(2):2635. PubMed ID: 35919789
[TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin-induced hypersensitivity reactions: risk factors and management.
Selcuk A; Yıldız B
Eur Rev Med Pharmacol Sci; 2023 Mar; 27(6):2640-2645. PubMed ID: 37013782
[TBL] [Abstract][Full Text] [Related]
18. Variant hypersensitivity reaction (HSR) presented with persistent dry cough after receiving oxaliplatin in a pancreatic cancer patient.
Li J; Peccerillo J; Kaley K; Saif MW
Iran J Allergy Asthma Immunol; 2009 Sep; 8(3):165-8. PubMed ID: 20124609
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcomes of rapid desensitisation protocols for chemotherapeutic agents and monoclonal antibodies following hypersensitivity reactions.
Kuo JC; Hawkins C; Yip D
Intern Med J; 2014 May; 44(5):442-9. PubMed ID: 24393214
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
